|Actavis Confirms District Court Ruling In Generic Lialda Patent Suit; Vermillion Announces Equity Financing|
|By Staff and Wire Reports|
|Thursday, 09 May 2013 18:26|
Actavis (NYSE: ACT) confirmed that the United States District Court for the Southern District of Florida has found United States Patent No. 6,773,720 (the '720 Patent) valid and infringed by Actavis' generic version of Shire's Lialda® (mesalamine extended-release tablets). Actavis is reviewing the court's decision and will evaluate all available options, including an appeal.
Lialda® is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC. Actavis' Abbreviated New Drug Application ("ANDA") for its generic version of Lialda® is currently pending with the U.S. Food and Drug Administration (FDA).
Vermillion, Inc. (NASDAQ:VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, announced Oracle Investment Management, Jack W. Schuler, Matthew W. Strobeck and other investors, have agreed, subject to closing conditions, to make an initial investment of $13.2 million by purchasing 8.0 million shares of the Company's common stock. Upon the closing of the transaction, Vermillion will be issuing the investors 12.5 million warrants with a strike price of $1.46. If and when the warrants are exercised, the company will realize an additional $18.3 million in proceeds, bringing the total investment to $31.5 million, before transaction costs.
Proceeds from this transaction will be used to increase test sales and improve reimbursement for OVA1, expand the commercial opportunity into new markets and advance one or more next-generation ovarian cancer diagnostic tests.
Abbott (NYSE: ABT) today announced CE Marking (Conformité Européenne) for the ARCHITECT clinical chemistry Hemoglobin A1c (HbA1c) test, which may aid physicians in diagnosing and monitoring diabetes as well as identifying patients at risk for developing diabetes.
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) announces the results of the vote on directors held earlier today at its annual meeting of shareholders.
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the first quarter ended March 31, 2013.
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and to improve lipid profiles in humans, today announced that its Russian licensing partner CardioNova has received written notification of approval of the Phase 1 protocol in its Investigational New Drug (IND) application with the Ministry of Healthcare of the Russian Federation (Minzdrav).
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013, with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's recent achievements and an update on business operations and upcoming milestones for 2013.
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the first quarter ended March 31, 2013 and provided a business update on its clinical trials of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.
China Biologic Products, Inc. (NASDAQ: CBPO), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the first quarter of 2013.
Cornerstone Therapeutics Inc. (NASDAQ: CRTX), a specialty pharmaceutical company focused on commercializing products for the U.S. hospital and adjacent specialty markets, today announced results for the first quarter ended March 31, 2013.
Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, today reported financial results for the three months ended March 31, 2013.
Depomed, Inc. (Nasdaq: DEPO) today reported financial results for the quarter ended March 31, 2013.
Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that it is offering to sell shares of its common stock in an underwritten public offering.
EasyMed Services Inc. (CNSX:EZM) (PINKSHEETS:EMYSF) (MUN:EY6) announces that the report of a large-scale study conducted by the University Hospital of Geneva, using EasyMed's Easy SmartCare technology, has been published in the BMC Health Service Research journal (2013 Apr 4;13:125) and is now available online with open-access publisher, BioMed Central.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, is scheduled to present at the Bank of America Merrill Lynch 2013 Healthcare Conference at the Encore at the Wynn in Las Vegas, Nevada on Wednesday, May 15, 2013.
Esterline Technologies (NYSE: ESL) plans to announce financial results for its 2nd quarter 2013 on Thursday, May 30, 2013. Esterline will host a conference call featuring remarks by Brad Lawrence, President and Chief Executive Officer, and Bob George, Vice President and Chief Financial Officer.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter ended March 31, 2013.
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced that the Company has reached an agreement in principle to settle the consolidated securities class-action lawsuit related to the restatement of Hansen Medical's financial statements that was first announced in October 2009.
MusclePharm Corporation (OTCQB: MSLP), a nutritional supplement company focused on active lifestyles, plans to release its financial results for the first quarter ended March 31, 2013 after the market close on Wednesday, May 15, 2013.
Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2013.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas.
Omeros Corporation (NASDAQ: OMER) today announced that it has agreed to sell 3,903,004 shares of its common stock at a price of $4.14 per share, a two percent premium over the closing price on May 8, 2013, for gross proceeds of $16.2 million.
Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended March 31, 2013.
Oncothyreon Inc. (NASDAQ: ONTY) today reported financial results for the first quarter ending March 31, 2013.
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter ended March 31, 2013.
Oxford BioMedica plc (LSE: OXB), the leading gene-based biopharmaceutical company, today announces an update from the 2013 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) held in Seattle, Washington (USA) on 5-9 May 2013.
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2013.
Profit Planners Management, Inc. (OTCQB: PPMT) has created Organic Innovations, Inc. it was announced today.
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Bank of America Merrill Lynch 2013 Healthcare Conference in Las Vegas on May 14, 2013 at 4:20 PM PT/7:20 PM ET.
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it will present at the Bank of America Merrill Lynch Health Care Conference to be held at the Encore at Wynn hotel in Las Vegas, Nevada on Wednesday, May 15, 2013.
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2013 financial results and accomplishments.
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported revenue of $38.5 million for the first quarter of 2013, an increase of 158% compared to revenue of $14.9 million for the first quarter of 2012.
Sunshine Heart, Inc. (NASDAQ: SSH) announced today the implant of the first patient in the OPTIONS HF C-Pulse System Multicenter Study. The post market study is intended to treat patients with moderate to severe heart failure.
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic®development programs and an overview of the company's business strategy at 10:00 am PT on Thursday, May 16, 2013, at the Bank of America Merrill Lynch 2013 Health Care Conference which will be held in Las Vegas.
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the first quarter ended March 31, 2013.
Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported financial results for the first quarter ended March 31, 2013, and also provided full year 2013 financial guidance.
Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, joins ovarian cancer organizations around the world in recognizing May 8 as World Ovarian Cancer Day.